Expression of carbonic anhydrase IX in genitourinary and adrenal tumours

Histopathology

Volumn 59, Issue 6, 2011, Pages 1229-1239

  Donato, Daniel P ^a   Johnson, Matthew T ^a   Yang, Ximing J ^b   Zynger, Debra L ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adrenal; Carbonic anhydrase IX; Immunohistochemistry; Testis

Indexed keywords

CALRETININ; CARBONATE DEHYDRATASE IX; CD99 ANTIGEN; CYTOKERATIN 18; INHIBIN;

ADENOCARCINOMA; ADRENAL CORTEX ADENOMA; ADRENAL MEDULLA TUMOR; ADRENAL TUMOR; ANGIOMYOLIPOMA; ARTICLE; BLADDER TUMOR; CARCINOID; CHORIOCARCINOMA; CLEAR CELL CARCINOMA; EMBRYONAL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY CORTEX; KIDNEY PELVIS TUMOR; KIDNEY POLYCYSTIC DISEASE; LEYDIG CELL TUMOR; METAPLASIA; ONCOCYTOMA; PAPILLARY CARCINOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SEMINOMA; SERTOLI CELL TUMOR; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; TERATOMA; TRANSITIONAL CELL CARCINOMA; TUMOR DIFFERENTIATION; URETER TUMOR; UROGENITAL TRACT TUMOR; UROTHELIUM; YOLK SAC TUMOR;

ADRENAL GLAND NEOPLASMS; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; TUMOR MARKERS, BIOLOGICAL; UROGENITAL NEOPLASMS;

EID: 84862915006     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04074.x     Document Type: Article

References (42)

1. American Cancer Society. Cancer facts and figures. American Cancer Society, 2010. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/docume nts/document/acspc-026238.pdf (accessed 12 December 2010).
2. Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumour cell growth, survival, and invasion. Cancer Res. 2004; 64; 6160-6165.
3. Ivanov S, Liao SY, Ivanova A et al. Expression of hypoxia-inducible cell-surface transmembrane carvonic anhydrases in human cancer. Am. J. Pathol. 2001; 158; 905-919.
4. Turner KJ, Crew JP, Wykoff CC et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br. J. Cancer 2002; 86; 1276-1282.
5. Wykoff CC, Beasley NJ, Watson PH et al. Hypoxia-inducible expression of tumour-associated carbonic anhydrases. Cancer Res. 2000; 60; 7075-7083.
6. Driessen A, Landuyt W, Pastorekova S et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann. Surg. 2006; 243; 334-340.
7. Lee WY, Huang SC, Hsu KF et al. Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence. Gynecol. Oncol. 2008; 108; 377-384.
8. Loncaster JA, Harris AL, Davidson SE et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumour oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001; 61; 6394-6399.
9. Swinson DE, Jones JL, Richardson D et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumour hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J. Clin. Oncol. 2003; 21; 473-482.
10. Trastour C, Benizri E, Ettore F et al. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int. J. Cancer 2007; 120; 1451-1458.
11. Gupta R, Balzer B, Picken M et al. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am. J. Surg. Pathol. 2009; 33; 241-247.
12. Sandlund J, Oosterwijk E, Grankvist K et al. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int. 2007; 100; 556-560.
13. Tickoo SK, Alden D, Olgac S et al. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J. Urol. 2007; 177; 1258-1263.
14. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 2005; 11; 3714-3721.
15. Narita T, Yin S, Gelin CF et al. Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin. Cancer Res. 2009; 15; 6128-6136.
16. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 2003; 9; 802-811.
17. Chen YT, Tu JJ, Kao J et al. Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin. Cancer Res. 2005; 11; 6558-6566.
18. Grabmaier K, Vissers JL, De Weijert MC et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int. J. Cancer 2000; 85; 865-870.
19. Liao SY, Aurelio ON, Jan K et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 1997; 57; 2827-2831.
20. Choueiri TK, Regan MM, Rosenberg JE et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010; 106; 772-778.
21. Gobbo S, Eble JN, Grignon DJ et al. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am. J. Surg. Pathol. 2008; 32; 1239-1245.
22. Klatte T, Seligson DB, Rao JY et al. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer 2009; 115; 1448-1458.
23. Hoskin PJ, Sibtain A, Daley FM et al. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br. J. Cancer 2003; 89; 1290-1297.
24. Sherwood BT, Colquhoun AJ, Richardson D et al. Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer. Clin. Oncol. 2007; 19; 777-783.
25. Liao SY, Lerman MI, Stanbridge EJ. Expression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development. BMC Dev. Biol. 2009; 9; 22.
26. Jensen RL, Gillespie D, House P et al. Endolymphatic sac tumours in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression. J. Neurosurg. 2004; 100; 488-497.
27. Karhumaa P, Kaunisto K, Parkkila S et al. Expression of the transmembrane carbonic anhydrases, CA IX and CA XII, in the human male excurrent ducts. Mol. Hum. Reprod. 2001; 7; 611-616.
28. Smyth LG, O'Hurley G, O'Grady A et al. Carbonic anhydrase IX expression in prostate cancer. Prostate Cancer Prostatic Dis. 2010; 13; 178-181.
29. Chopra S, Foltz WD, Milosevic MF et al. Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int. J. Radiat. Biol. 2009; 85; 805-813.
30. Anai S, Shiverick K, Medrano T et al. Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization. Urology 2007; 70; 832-837.
31. Genis C, Sippel KH, Case N et al. Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties. Biochemistry 2009; 48; 1322-1331.
32. Li G, Feng G, Gentil-Perret A et al. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J. Urol. 2008; 180; 510-513.
33. Stewart GD, Nanda J, Brown DJ et al. NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int. J. Cancer 2009; 124; 223-232.
34. Zhou GX, Ireland J, Rayman P et al. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. Urology 2010; 75; 257-261.
35. Hyrsl L, Zavada J, Zavadova Z et al. Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract. Neoplasma 2009; 56; 298-302.
36. Divgi CR, Pandit-Taskar N, Jungbluth AA et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007; 8; 304-310.
37. Bui MH, Visapaa H, Seligson D et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J. Urol. 2004; 171; 2461-2466.
38. Kim HL, Seligson D, Liu X et al. Using tumour markers to predict the survival of patients with metastatic renal cell carcinoma. J. Urol. 2005; 173; 1496-1501.
39. Patard JJ, Fergelot P, Karakiewicz PI et al. Low CAIX expression and absence of VHL gene mutation are associated with tumour aggressiveness and poor survival of clear cell renal cell carcinoma. Int. J. Cancer 2008; 123; 395-400.
40. Wang Y, Wang XY, Subjeck JR et al. Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant. Mol. Cancer Ther. 2008; 7; 3867-3877.
41. Leibovich BC, Sheinin Y, Lohse CM et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J. Clin. Oncol. 2007; 25; 4757-4764.
42. Hussain SA, Palmer DH, Ganesan R et al. Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncol. Rep. 2004; 11; 1005-1010.